GSK's Volibris Drug Approved for Combination Treatment
November 24 2015 - 6:47AM
Dow Jones News
By Razak Musah Baba
LONDON--GlaxoSmithKline PLC (GSK.LN) said Tuesday that it has
received approval from the European Commission to widen the
application of its drug Volibris to treat pulmonary arterial
hypertension.
The pharmaceutical firm said the European Commission has
approved a variation of the drug to expand the current therapeutic
indication for Volibris (ambrisentan). The drug can now be used as
part of a combination treatment for patients with pulmonary
arterial hypertension.
PAH is a disease characterized by constriction of the blood
vessels in the lungs leading to high pulmonary arterial
pressures.
Shares at 1100 GMT down 0.14 pence, or 1.04%, at GBP13.31,
valuing the company at GBP64.78 billion.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 24, 2015 06:32 ET (11:32 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
